ERBB2 and non-small cell lung carcinoma: Afatinib, a second-generation irreversible EGFR tyrosine kinase inhibitor (TKI), targets EGFR mutation-positive NSCLC by broadly inhibiting receptors including EGFR, HER2, and HER4.